Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF NOVEMBER 20, 2019 SAM #6565
SOLICITATION NOTICE

65 -- Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program

Notice Date

11/18/2019 6:00:08 AM
 

Notice Type

Solicitation
 

NAICS

325412 — Pharmaceutical Preparation Manufacturing
 

Contracting Office

DEFENSE HEALTH AGENCY - AURORA AURORA CO 80011 USA
 

ZIP Code

80011
 

Solicitation Number

HT9402-20-Q-0001(1)
 

Response Due

12/3/2019 10:00:00 AM
 

Archive Date

03/01/2020
 

Point of Contact

Yvette Dluhos, Alexia Ray
 

E-Mail Address

yvette.h.dluhos.civ@mail.mil, alexia.m.ray.ctr@mail.mil
(yvette.h.dluhos.civ@mail.mil, alexia.m.ray.ctr@mail.mil)
 

Description

Background:The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.P&T COMMITTEE MEETING: February 2020: The following drug classes/subclass and newly approved agents will be reviewed:Acne Agents, SUB CLASS: Topical Acne and Rosacea - AkliefPulmonary 1-Agents, SUB CLASS: Pulmonary Miscellaneous - FasenraAntigout Agents, SUB CLASS: Acute - GloperbaSkeletal Muscle Relaxants and Combinations, SUB CLASS: NA - OzobaxPulmonary - 1 Agents, SUB CLASS: Short Acting Beta Agonists - ProairDigihalerCystic Fibrosis Agents, SUB CLASS: NA - TrikaftaMultiple Sclerosis Agents, SUB CLASS: Methy Fumarate - VumerityRFQ: The RFQ, including UF BPA and UF ADP appendices are attached herein.There is no pre-proposal teleconference for Newly Approved Drugs RFQ. Questions shall besubmitted via e-mail to the RFQ Point of Contact stated in Part 2.3, no later than the date stated in Part 2.4. Also, responses to Part 3.4 is required.POCs: Part 2.3 of the RFQ. For additional information, search DoD Pharmacy and Therapeutics (P&T)Committee at http://www.health.mil/POD
 

Web Link

SAM.gov Permalink
(https://beta.sam.gov/opp/e22b021330c94ad0815a212fa7dbb5a7/view)
 

Place of Performance

Address: 65000, TX 78230, USA

Zip Code: 78230

Country: USA
 

Record

SN05497944-F 20191120/191120064125 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |